A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: relapse peripheral T-cell lymphoma | cancer
Age: Between 18 - 100 Years
Gender: Male or Female
Recruitment StatusEnrolling By Invitation
If you need help finding a study or have any questions, please contact us at email@example.com or by phone at (888) 264-0005.